KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Share-based Compensation for 6 consecutive years, with $23.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 22.81% year-over-year to $23.8 million, compared with a TTM value of $111.2 million through Dec 2025, up 36.16%, and an annual FY2025 reading of $111.2 million, up 36.16% over the prior year.
  • Share-based Compensation was $23.8 million for Q4 2025 at Recursion Pharmaceuticals, down from $25.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $36.1 million in Q1 2025 and bottomed at $1.8 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $14.5 million, with a median of $13.9 million recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 591.42% in 2021, then decreased 22.81% in 2025.
  • Year by year, Share-based Compensation stood at $4.3 million in 2021, then soared by 77.26% to $7.7 million in 2022, then soared by 109.04% to $16.1 million in 2023, then skyrocketed by 91.37% to $30.8 million in 2024, then fell by 22.81% to $23.8 million in 2025.
  • Business Quant data shows Share-based Compensation for RXRX at $23.8 million in Q4 2025, $25.2 million in Q3 2025, and $26.2 million in Q2 2025.